查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1673815

製药和生物技术行业探索阶段合作条款和协议（2020-2025年）

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2020-2025
出版日期: | 出版商: Current Partnering | 英文 2500+ Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告研究了製药和生物技术行业的探索阶段合作条款和协议，并提供了全面的资料驱动分析，说明公司如何以及为何签订探索阶段合作协议，以及这些协议所依据的财务和战略条款。本报告还深入洞察了製药和生物技术产业早期联盟的结构、谈判动态和财务考量。

在药物探索阶段，授权协议通常授予被授权人进一步开发授权人的产品或技术的权利或选择权。这些协议通常包含多个部分，从合作研究与开发（R&D）开始，并可能达成商业化协议。

本报告详细分析了医疗保健领域最新的探索阶段交易，以帮助公司了解市场趋势，评估竞争对手的交易结构，并最佳化自己的谈判策略。

本报告提供：

  • 2020年及以后生物製药产业药物探索阶段交易趋势分析
  • 了解财务结构，包括预付款、里程碑付款和特许权使用费
  • 真实药物探索阶段合约案例研究
  • 可存取 2,690 多个探索阶段交易（如有交易记录，另行提供）
  • 2020年及以后最活跃的药物发现交易者简介
  • 对最高价值药物探索阶段交易的详细分析

目录

执行摘要

第1章 简介

第2章 为什么企业在临床阶段合作

  • 合作在药物研发中的作用
    • 探索阶段的许可
    • 探索阶段的许可
  • 区分发现、临床前和临床阶段的交易
  • 在药物研发过程中签订合作协议的原因
    • 授权商为何参与探索阶段的交易
    • 为什么被授权人参与探索阶段的交易
  • 探索阶段合作交易的未来

第3章 探索阶段的交易策略与结构

  • 公司在什么阶段进行合作？
    • 製药/生技领域的早期合作
    • 製药/生技联盟
  • 早期与晚期伙伴关係：风险与成本
  • 各公司在发现、临床前和临床阶段合作上花了多少？
  • 纯合作协议与多部分合作协议
  • 纯许可合约结构
    • 纯许可协议范例
    • 个案研究
  • 多部分药物探索阶段合作协议
    • 多部分早期条款范例
    • 个案研究

第4章 探索阶段伙伴关係的付款策略

  • 探索阶段的支付策略
  • 付款方式
    • 标题
    • 预付
    • 贷款
    • 可转换贷款
    • 公平
    • 研发资金
    • 许可证费用
    • 里程碑
    • 版税
    • 现金
    • 选择

第5章 探索阶段交易趋势

  • 长期探索阶段伙伴关係
  • 探索阶段合作伙伴关係（依交易类型）
  • 依疾病类型的探索阶段伙伴关係
  • 依技术类型的药物探索阶段合作伙伴关係
  • 最活跃的企业探索阶段合作

第6章 探索阶段伙伴关係的付款条款

  • 探索阶段的付款条款指南
    • 预付
    • 里程碑
    • 版税
  • 药物研发中的付款条款：交易资料分析
    • 公开资料
    • 调查资料
  • 付款条件分析
    • 探索阶段的主要资料
    • 探索阶段交易的预付款
    • 药物探索阶段交易的里程碑付款
    • 药物研发过程中的专利费率

第7章 关键探索阶段交易

  • 价值最高的探索阶段交易

第8章 25 大药物研发交易者

  • 25 位最活跃的探索阶段交易者

第9章 探索阶段合作协议目录

  • 2020年至2025年的探索阶段交易

第10章 探索阶段交易：依开发阶段

  • 依探索阶段的交易

附录

简介目录
Product Code: CP2056

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025)

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report offers a comprehensive, data-driven analysis of how and why companies engage in discovery-stage partnering deals and the financial and strategic terms underpinning these agreements. This essential industry resource provides deep insights into the structure, negotiation dynamics, and financial considerations that define early-stage partnerships in the pharmaceutical and biotech sectors.

At the discovery stage, licensing agreements typically grant the licensee rights or options to further develop a licensor's product or technology. These agreements are often multi-component, beginning with collaborative research and development (R&D) and potentially leading to commercialization agreements.

This report provides a detailed breakdown of the latest discovery-stage agreements in the healthcare sector, helping companies identify market trends, evaluate competitive deal structures, and optimize their own negotiation strategies.

A Must-Have Resource for Biotech and Pharma Dealmakers

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report is an indispensable resource for business development, legal, and financial professionals involved in biopharma dealmaking.

With comprehensive insights, a vast deal database, and direct access to contract documents, this report serves as the ultimate tool for:

  • Benchmarking deal structures and financial terms
  • Optimizing negotiation strategies
  • Assessing potential partners' flexibility and deal-making behavior
  • Identifying trends and best practices in discovery-stage partnerships
  • For those looking to navigate the complex landscape of discovery-stage partnering, this report offers the clarity, data, and strategic guidance needed to secure high-value agreements with the right partners.
  • Why This Report is Essential for Dealmakers
  • Gaining insight into the flexibility and negotiation strategies of potential partners is crucial in structuring a successful discovery-stage deal. While headline financial terms (e.g., upfront payments, milestones, and royalties) provide a broad overview, contract documents offer a deeper understanding of the actual triggers and conditions for these payments-critical details that press releases and traditional databases often omit.
  • This report contains a comprehensive listing of all discovery-stage partnering deals announced since 2020, including financial terms where available. It also features over 2,690 links to detailed online deal records, including publicly available contract documents filed with the SEC.
  • By analyzing these agreements, companies gain a competitive edge in structuring deals that align with industry benchmarks while maximizing potential returns.
  • Comprehensive Analysis of Discovery-Stage Partnering Trends

The first chapters of the report provide a detailed orientation to discovery-stage deal-making and strategic considerations:

Chapter 1 - Introduction to the report

Chapter 2 - Why companies engage in discovery-stage partnerships

Chapter 3 - Strategic approaches and deal structures, with case studies

Chapter 4 - Payment strategies, including upfronts, milestones, and royalties

Chapter 5 - Discovery-stage deal-making analysis (2020-2025), categorized by year, therapeutic area, technology type, and key dealmakers

Chapter 6 - Detailed analysis of financial terms, including headline values, upfront payments, milestone triggers, and royalty rates

Chapter 7 - A review of the leading discovery-stage deals by headline value

Chapter 8 - The top 25 most active discovery-stage dealmakers

Chapter 9 - A database of discovery-stage partnering agreements, including contract documents where available

Chapter 10 - A comprehensive directory of all discovery-stage deals announced since 2020

  • Each deal record is linked to Current Agreements, a proprietary database that provides easy access to full deal structures, financial terms, and contract documents.
  • Key Benefits of the Report
  • Comprehensive insights into discovery-stage deal trends since 2020
  • Access to key financial terms, including headline values, upfronts, milestones, and royalty structures
  • Breakdown of deal structures, with real-world case studies
  • Analysis of contractual terms, including real-world clause examples
  • Benchmarking of deal terms based on actual agreements
  • Due diligence insights to assess the suitability of proposed deal terms for potential partners
  • Scope of the Report

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report provides:

  • Analysis of discovery-stage dealmaking trends in the biopharma industry since 2020
  • Insight into financial structures, including upfront, milestone, and royalty payments
  • Case studies of real-life discovery-stage agreements
  • Access to over 2,690 discovery-stage deals, with contract records where available
  • Profiles of the most active discovery-stage dealmakers since 2020
  • Detailed analysis of the highest-value discovery-stage deals

Each deal record is indexed by:

  • Company (A-Z)
  • Headline Value
  • Stage of Development at Signing
  • Deal Type
  • Specific Therapy Focus
  • For easy access, every deal record links to an online version, and where available, the full contract document.
  • Critical Questions Answered

By analyzing actual contract agreements where available, this report provides definitive answers to critical questions such as:

  • What specific rights are granted in each agreement?
  • What exclusivity terms apply?
  • How is the deal structured financially? (Upfronts, milestones, royalties)
  • How are sales and payments audited?
  • Who controls development, manufacturing, and commercialization?
  • How is intellectual property handled?
  • How are confidentiality and publication rights managed?
  • Under what conditions can a deal be terminated?
  • What dispute resolution mechanisms are in place?
  • What happens in the event of a change in ownership?
  • Gain the competitive edge-explore the report today.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner at discovery stage?

  • 2.1. Introduction
  • 2.2. The role of discovery stage partnering
    • 2.2.1. In-licensing at discovery stage
    • 2.2.2. Out-licensing at discovery stage
  • 2.3. Difference between discovery, preclinical and clinical stage deals
  • 2.4. Reasons for entering into discovery stage partnering deals
    • 2.4.1. Licensors reasons for entering discovery stage deals
    • 2.4.2. Licensees reasons for entering discovery stage deals
  • 2.5. The future of discovery stage partnering deals

Chapter 3 - Discovery stage deal strategies and structure

  • 3.1. Introduction
  • 3.2. At what stage do companies partner?
    • 3.2.1. Partnering early in pharmaceutical/biotech
    • 3.2.1.1. Discovery and preclinical stage partnering case studies
    • 3.2.1.1.a. Case study 1
    • 3.2.1.1.b. Case study 2
    • 3.2.1.1.c. Case study 3
    • 3.2.1.1.d. Case study 4
    • 3.2.2. Partnering later in pharmaceutical/biotech
    • 3.2.2.1. Clinical stage partnering case studies
    • 3.2.2.1.a. Case study 5
    • 3.2.2.1.b. Case study 6
    • 3.2.2.1.c. Case study 7
    • 3.2.2.1.d. Case study 8
  • 3.3. Early and later stage partnering - a risk/cost comparison
  • 3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
  • 3.5. Pure versus multi-component partnering deals
  • 3.6. Pure licensing agreement structure
    • 3.6.1. Example pure licensing agreements
    • 3.6.1.a. Case study 9
    • 3.6.1.b. Case study 10
  • 3.7. Multicomponent discovery stage partnering agreements
    • 3.7.1.a. Example multicomponent early stage clauses
    • 3.7.1.a. Case study 11
    • 3.7.1.b. Case study 12

Chapter 4 - Discovery stage partnering payment strategies

  • 4.1. Introduction
  • 4.2. Discovery stage payment strategies
  • 4.3. Payment options
    • 4.3.1. Headline values
    • 4.3.2. Upfront payments
    • 4.3.2.1. Conditionality of upfront payments
    • 4.3.3. Loans
    • 4.3.4. Convertible loans
    • 4.3.5. Equity
    • 4.3.6. R&D funding
    • 4.3.7. Licensing fees
    • 4.3.8. Milestone payments
    • 4.3.9. Royalty payments
    • 4.3.9.1. Issues affecting royalty rates
    • 4.3.9.2. Royalties on combination products
    • 4.3.9.2.a. Case study 13
    • 4.3.9.3. Guaranteed minimum/maximum annual payments
    • 4.3.9.4. Royalty stacking
    • 4.3.9.5. Royalties and supply/purchase contracts
    • 4.3.10. Quids
    • 4.3.11. Option payments

Chapter 5 - Trends in discovery stage deal making

  • 5.1. Introduction
  • 5.2. Discovery stage partnering over the years
    • 5.2.1. Attributes of discovery deals
  • 5.3. Discovery stage partnering by deal type
  • 5.4. Discovery stage partnering by disease type
  • 5.5. Partnering by discovery stage technology type
  • 5.6. Discovery stage partnering by most active company, 2020 to 2025

Chapter 6 - Payment terms for discovery stage partnering

  • 6.1. Introduction
  • 6.2. Guidelines for discovery stage payment terms
    • 6.2.1. Upfront payments
    • 6.2.2. Milestone payments
    • 6.2.3. Royalty payments
  • 6.3. Discovery stage payment terms - deal data analysis
    • 6.3.1. Public data
    • 6.3.2. Survey data
  • 6.4. Payment terms analysis
    • 6.4.1. Discovery stage headline values
    • 6.4.2. Discovery stage deal upfront payments
    • 6.4.3. Discovery stage deal milestone payments
    • 6.4.4. Discovery stage royalty rates

Chapter 7 - Leading discovery stage deals

  • 7.1. Introduction
  • 7.2. Top discovery stage deals by value

Chapter 8 - Top 25 most active discovery stage dealmakers

  • 8.1. Introduction
  • 8.2. Top 25 most active discovery stage dealmakers

Chapter 9 - Discovery stage partnering contracts directory

  • 9.1. Introduction
  • 9.2. Discovery stage deals with contracts 2020 to 2025

Chapter 10 - Discovery stage deal making by development stage

  • 10.1. Introduction
  • 10.2. Deals by discovery stage

Appendices

  • Appendix 1 - Discovery stage dealmaking by companies A-Z
  • Appendix 2 - Discovery stage dealmaking by industry sector
  • Appendix 3 - Discovery stage dealmaking by stage of development
  • Appendix 4 - Discovery stage dealmaking by therapy area
  • Appendix 5 - Discovery stage dealmaking by technology type
  • About Biopharma Research Ltd
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
  • Figure 3: Components of the pure licensing deal structure
  • Figure 4: Payment options for discovery stage partnering deals
  • Figure 5: Issues affecting royalty rates
  • Figure 6: Discovery stage partnering frequency 2020 - 2025
  • Figure 7: Discovery stage partnering by deal type since 2020
  • Figure 8: Discovery stage partnering by disease type since 2020
  • Figure 9: Discovery stage partnering by technology type since 2020
  • Figure 10: Top 25 most active discovery stage dealmakers, 2020 to 2025
  • Figure 11: Review of median upfront payments for discovery stage deals
  • Figure 12: Review of median milestone payments for discovery stage deals
  • Figure 13: Review of median royalty payments for discovery stage deals
  • Figure 14: Discovery stage deals with a headline value
  • Figure 15: Discovery stage deals with an upfront value
  • Figure 16: Discovery stage deals with a milestone value
  • Figure 17: Discovery stage deals with a royalty rate value
  • Figure 18: Top discovery stage deals by deal value since 2020
  • Figure 19: Most active discovery stage dealmakers 2020 to 2025